Sector Analysis: Semiconductors, Biotech, Energy

Sector Analysis: semiconductors, biotech, energy

Sector analysis (Sector Analysis) is an integral part of the investment selection process (Stock Selection), allowing one to identify structural trends, industry cyclicality, and sector-specific value drivers. For a manager of a large portfolio, a deep understanding of sector dynamics determines the ability to generate alpha (Alpha Generation) through correct positioning in leading sectors and avoiding structurally weak industries. In this article, we will examine three key sectors with the highest potential for long-term growth: semiconductors (Semiconductors), biotechnology (Biotechnology), and energy (Energy/Power Generation), analyzing the specific metrics, cycles, and investment opportunities of each sector.

Semiconductors: Micron, Nvidia, and Memory Demand Cycles

The semiconductor industry (Semiconductor Industry) is the foundation of the digital economy and is undergoing a structural transformation driven by three megatrends: artificial intelligence (AI/ML), electrification of transport (EV), and expansion of cloud infrastructure (Cloud Infrastructure).

Nvidia (NVDA) dominates the GPU segment for AI training (Training) and inference (Inference) with a market share of 80–90% in data centers. Key metrics for analyzing Nvidia:

Data Center revenue growth — the main driver of re-rating, reaching $47B+ in the 2024 fiscal year;
Gross Margin — 70–75%, reflecting monopolistic pricing power (Pricing Power) in AI chips;
Design Win pipeline — the number of design wins in new AI platforms, determining future revenue over a 12–18 month horizon.

Micron Technology (MU) is the largest American memory manufacturer (DRAM and NAND), whose business is distinguished by pronounced cyclicality (Cyclicality). Memory demand cycles (Memory Demand Cycles) are determined by supply-demand balance (Supply-Demand Balance):

In the shortage phase (Supply Shortage), DRAM prices rise by 30–50%, Micron’s margin expands to 30–40% Operating Margin;
In the oversupply phase (Oversupply), prices fall by 20–40%, and the company can turn unprofitable.

The key cycle indicator is the dynamics of the average selling price (Average Selling Price, ASP): ASP growth signals the start of the upward phase of the cycle, while decline — the downward phase.

AI workloads are creating a structural shift in demand for High Bandwidth Memory (HBM) — specialized memory for AI accelerators: Micron is investing $8–10B CAPEX in expanding HBM production, which provides a premium ASP 3–5 times higher than standard DRAM.

Analyzing the semiconductor sector requires tracking specific leading indicators:

WSTS (World Semiconductor Trade Statistics) — monthly global shipment and billing data;
SIA (Semiconductor Industry Association) — regional sales statistics;
SOX index (Philadelphia Semiconductor Index) — the sector benchmark;
SEMI Equipment Billings — orders for semiconductor equipment, a leading indicator of capital cycles;
inventory-to-revenue ratio — the level of inventories relative to revenue, an indicator of oversupply or shortage in the supply chain.

Biotech: Vertex, Regeneron, and Pipeline Analysis

The biotechnology sector (Biotechnology Sector) presents a unique investment opportunity with the highest return potential but also with significant specific risks: regulatory risk (Regulatory Risk), clinical trial risk (Clinical Trial Risk), and patent cliff (Patent Cliff).

Vertex Pharmaceuticals (VRTX) is an example of a successful biotech company: monopoly in cystic fibrosis treatment (Cystic Fibrosis, CF) through the Trikafta/Kaftrio drug line provides $9–10B in annual revenue with 40–45% Operating Margin.

Vertex analysis includes:

evaluation of the drug pipeline (Pipeline Analysis) — the portfolio of drugs at various stages of clinical trials (Phase 1, 2, 3);
probability of FDA approval (Probability of Approval, PoA) for each candidate;
Net Present Value (NPV) of the pipeline — the discounted value of expected future cash flows from each drug, factoring in success probability.

Regeneron Pharmaceuticals (REGN) demonstrates a model of successful diversification:

the flagship drug Eylea (retinal diseases treatment) generates $6B+ in revenue,
Dupixent (dermatitis, asthma, in partnership with Sanofi) — $12B+ in global sales,
Libtayo (oncology) expands their presence in immuno-oncology.

Key risks for biotechnology companies include:

patent cliff (Patent Cliff) — loss of exclusivity after the patent expires leads to biosimilars entering (Biosimilars) and revenue falling by 60–80% over 2–3 years;
FDA regulatory risk (FDA Approval Risk) — a Complete Response Letter (CRL, denial of approval) can crash capitalization by 30–50% in a single day;
IRA (Inflation Reduction Act) — the right of Medicare to negotiate drug prices creates drug pricing pressure (Drug Pricing Pressure) for the largest drugs.

Valuation methodology for biotech companies:

Sum-of-the-Parts (SOTP) — each drug and pipeline candidate is evaluated separately through risk-adjusted NPV (rNPV), where drug cash flows are discounted by the probability of success at each stage of clinical trials.

Historical probabilities of success by stage (BIO/Informa):

Phase 1 → Phase 2: 52%;
Phase 2 → Phase 3: 29%;
Phase 3 → FDA Approval: 58%;
overall probability from Phase 1 to approval: ~8–10%.

For companies with approved blockbusters (Blockbuster Drugs — drugs with revenue >$1B), the valuation is structured as the sum of DCF for approved products (taking into account the patent cliff timeline) + rNPV of the pipeline + technology platform value (Platform Value).

Energy: GE Vernova and Energy Sector Transformation

The energy sector (Energy Sector) is undergoing fundamental transformation, driven by three parallel processes: decarbonization (Decarbonization) — transition from fossil fuels to renewable energy sources; electrification (Electrification) — increased electricity consumption due to data centers (AI/ML workloads), electric vehicles (EV), and heat pumps (Heat Pumps); grid modernization (Grid Modernization) — upgrading the aging infrastructure of power transmission and distribution.

GE Vernova (GEV) — spun off from General Electric — is an ideal subject for analyzing these trends: its portfolio includes gas turbines (Gas Power), wind turbines (Wind), electrical grids (Electrification), and small modular nuclear reactor technologies (Small Modular Reactors, SMR).

Key metrics for analyzing GE Vernova and similar energy equipment companies:

Order Backlog — the total value of signed but not yet fulfilled contracts; for GE Vernova, the backlog exceeds $100B, providing revenue visibility for 3–5 years ahead.
Book-to-Bill Ratio — the ratio of new orders to deliveries: a value >1.0 signals growing demand,

The investment thesis in the energy sector is built on a CAPEX supercycle (CAPEX Supercycle): global investments in energy infrastructure must grow from $2.8 trillion in 2023 to $4.5–5.0 trillion by 2030 (IEA World Energy Outlook).

AI data centers require enormous amounts of electricity: a large AI cluster consumes 50–100 MW, and planned giga–data centers — 500 MW–1 GW. This creates unprecedented demand for gas turbines (as a “bridge” technology — Bridge Technology), renewable energy, and energy storage systems (Energy Storage Systems, ESS).

For a portfolio manager, the energy sector offers an attractive combination: stable dividend yield (Dividend Yield 2–4%), structural revenue growth (Revenue Growth 8–15%), and inflation protection through price-indexed contracts.

Risks include: political risk (changes in subsidies and regulatory environment), technology risk (rapid technological evolution may render current assets obsolete), and project risks (overruns, delays, warranty claims).